Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study

Lang, Manlin1,2; Liang, Ping25; Shen, Huiming3; Li, Hang4; Yang, Ning5; Chen, Bo6; Chen, Yixu7; Ding, Hong8; Yang, Weiping9; Ji, Xiaohui10; Zhou, Ping11; Cui, Ligang12; Wang, Jiandong13; Xu, Wentong13; Ye, Xiuqin14; Liu, Zhixing15; Yang, Yu16; Wei, Tianci17; Wang, Hui18; Yan, Yuanyuan19; Wu, Changjun20; Wu, Yiyun21; Shi, Jingwen22; Wang, Yaxi23; Fang, Xiuxia23; li, Ran24; Yu, Jie25

2023-05-30

10.1186/s13058-023-01650-3

BREAST CANCER RESEARCH   影响因子和分区

1465-5411

1465-542X

BackgroundMultiparametric magnetic resonance imaging (MP-MRI) has high sensitivity for diagnosing breast cancers but cannot always be used as a routine diagnostic tool. The present study aimed to evaluate whether the diagnostic performance of perfluorobutane (PFB) contrast-enhanced ultrasound (CEUS) is similar to that of MP-MRI in breast cancer and whether combining the two methods would enhance diagnostic efficiency.Patients and methodsThis was a head-to-head, prospective, multicenter study. Patients with breast lesions diagnosed by US as Breast Imaging Reporting and Data System (BI-RADS) categories 3, 4, and 5 underwent both PFB-CEUS and MP-MRI scans. On-site operators and three reviewers categorized the BI-RADS of all lesions on two images. Logistic-bootstrap 1000-sample analysis and cross-validation were used to construct PFB-CEUS, MP-MRI, and hybrid (PFB-CEUS + MP-MRI) models to distinguish breast lesions.ResultsIn total, 179 women with 186 breast lesions were evaluated from 17 centers in China. The area under the receiver operating characteristic curve (AUC) for the PFB-CEUS model to diagnose breast cancer (0.89; 95% confidence interval [CI] 0.74, 0.97) was similar to that of the MP-MRI model (0.89; 95% CI 0.73, 0.97) (P = 0.85). The AUC of the hybrid model (0.92, 95% CI 0.77, 0.98) did not show a statistical advantage over the PFB-CEUS and MP-MRI models (P = 0.29 and 0.40, respectively). However, 90.3% false-positive and 66.7% false-negative results of PFB-CEUS radiologists and 90.5% false-positive and 42.8% false-negative results of MP-MRI radiologists could be corrected by the hybrid model. Three dynamic nomograms of PFB-CEUS, MP-MRI and hybrid models to diagnose breast cancer are freely available online.ConclusionsPFB-CEUS can be used in the differential diagnosis of breast cancer with comparable performance to MP-MRI and with less time consumption. Using PFB-CEUS and MP-MRI as joint diagnostics could further strengthen the diagnostic ability.Trial registration Clinicaltrials.gov; NCT04657328. Registered 26 September 2020.IRB number 2020-300 was approved in Chinese PLA General Hospital. Every patient signed a written informed consent form in each center.

PFB-CEUS MP-MRI Hybrid Diagnostic model Breast lesions Diagnostic performance

SCI

英语

其他

Oncology

Oncology

WOS:001000363700001

BMC

CLINICAL MEDICINE

Web of Science

1.Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Ultrasound, Med Ctr 5, Beijing 100039, Peoples R China
2.Chinese PLA Med Sch, Beijing 100039, Peoples R China
3.Southeast Univ, Zhongda Hosp, Dept Ultrasound, Nanjing 210009, Peoples R China
4.Putian Univ, Affiliated Hosp, Dept Breast Surg, Putian 351100, Peoples R China
5.Xingcheng Peoples Hosp, Dept Ultrasound, Xingcheng 125100, Peoples R China
6.Luan Peoples Hosp Anhui Prov, Dept Ultrasound Med, Liuan 237000, Peoples R China
7.Fifth Peoples Hosp, Dept Ultrasound, Chengdu 611130, Peoples R China
8.Huashan Hosp, Dept Ultrasound, Shanghai 200040, Peoples R China
9.Guangxi Med Univ, Dept Ultrasound, Canc Hosp, Nanning 530021, Peoples R China
10.Hebei Med Univ, Hosp 4, Dept Ultrasound, Shijiazhuang 050011, Peoples R China
11.Third Xiangya Hosp, Dept Ultrasound, Changsha 410000, Peoples R China
12.Peking Univ, Dept Ultrasound, Hosp 3, Beijing 100191, Peoples R China
13.Chinese Peoples Liberat Army Gen Hosp, Gen Surg, Beijing 100853, Peoples R China
14.Jinan Univ, Southern Univ Sci & Technol, Affiliated Hosp 1, Clin Coll 2,Dept Ultrasound,Shenzhen Med Ultrasoun, Shenzhen 518020, Peoples R China
15.Nanchang Univ, Affiliated Hosp 1, Dept Ultrasound Med, Nanchang 330006, Peoples R China
16.Beijing Friendship Hosp, Dept Ultrasound, Beijing 100050, Peoples R China
17.2nd Affiliated Hosp Harbin, Dept Ultrasound, Harbin 150001, Peoples R China
18.Jilin Univ, China Japan Union Hosp, Dept Ultrasound, Changchun 130033, Peoples R China
19.Zhengzhou Cent Hosp, Dept Ultrasound, Zhengzhou 450000, Peoples R China
20.Harbin Med Univ, Affiliated Hosp 1, Dept Ultrasonog, Harbin 150001, Peoples R China
21.Nanjing Univ Chinese Med, Affiliated Hosp, Dept Ultrasound, Nanjing 210029, Peoples R China
22.China Med Univ, Dept Ultrasound, Shengjing Hosp, Shenyang 110004, Peoples R China
23.Inner Mongolia Med Univ, Affiliated Hosp, Dept Ultrasound, Hohhot 010050, Peoples R China
24.Xinxiang Med Univ, Affiliated Hosp 1, Dept Ultrasound, Xinxiang 453100, Peoples R China
25.Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Dept Intervent Ultrasound, Beijing 100039, Peoples R China

Lang, Manlin,Liang, Ping,Shen, Huiming,et al. Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study[J]. BREAST CANCER RESEARCH,2023,25(1).

Lang, Manlin.,Liang, Ping.,Shen, Huiming.,Li, Hang.,Yang, Ning.,...&Yu, Jie.(2023).Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study.BREAST CANCER RESEARCH,25(1).

Lang, Manlin,et al."Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study".BREAST CANCER RESEARCH 25.1(2023).